BDX tops third-quarter fiscal 2025 earnings and margin estimates, with strong results from its Medical and Interventional segments.
Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Becton, Dickinson and Company (NYSE:BDX ) Q3 2025 Earnings Call August 7, 2025 8:00 AM ET Company Participants Christopher J. DelOrefice - Executive VP & CFO Greg Rodetis - Senior VP, Treasurer & Head of Investor Relations Thomas E.
![]() BOX 8 Sep 2020 | Other | €0.79 Per Share |
![]() BOX 8 Jun 2020 | Other | €0.79 Per Share |
![]() BOX 9 Mar 2020 | Other | €0.79 Per Share |
![]() BOX 9 Dec 2019 | Other | €0.79 Per Share |
![]() BOX 6 Sep 2019 | Other | €0.77 Per Share |
6 Nov 2025 (In 2 months) Date | | 3.99 Cons. EPS | - EPS |
7 Aug 2025 Date | | 3.42 Cons. EPS | 3.68 EPS |
31 Jul 2025 Date | | - Cons. EPS | - EPS |
1 May 2025 Date | | - Cons. EPS | - EPS |
30 Jan 2025 Date | | 2.99 Cons. EPS | 3.43 EPS |
![]() BOX 8 Sep 2020 | Other | €0.79 Per Share |
![]() BOX 8 Jun 2020 | Other | €0.79 Per Share |
![]() BOX 9 Mar 2020 | Other | €0.79 Per Share |
![]() BOX 9 Dec 2019 | Other | €0.79 Per Share |
![]() BOX 6 Sep 2019 | Other | €0.77 Per Share |
6 Nov 2025 (In 2 months) Date | | 3.99 Cons. EPS | - EPS |
7 Aug 2025 Date | | 3.42 Cons. EPS | 3.68 EPS |
31 Jul 2025 Date | | - Cons. EPS | - EPS |
1 May 2025 Date | | - Cons. EPS | - EPS |
30 Jan 2025 Date | | 2.99 Cons. EPS | 3.43 EPS |
Medical - Instruments & Supplies Industry | Healthcare Sector | Thomas E. Polen Jr. CEO | XMUN Exchange | US0758871091 ISIN |
US Country | 70,000 Employees | 8 Sep 2025 Last Dividend | 1 Apr 2022 Last Split | - IPO Date |
Becton, Dickinson and Company, commonly known as BD, is a global leader in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. Catering to healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public, BD operates worldwide. The company’s extensive product portfolio is strategically segmented into three core areas: BD Medical, BD Life Sciences, and BD Interventional. Founded in 1897, BD has established a robust presence in the healthcare sector, headquartered in Franklin Lakes, New Jersey.
This segment provides a comprehensive range of products, including peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, and vascular access technology. It also offers vascular care, preparation products, needle-free IV connectors, closed-system drug transfer devices, hazardous drug detections, and a variety of syringes and needles. For drug delivery and safety, it covers IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, as well as automated medication dispensing and supply management systems, enhancing medication inventory optimization and tracking. Additionally, BD Medical produces prefillable drug delivery systems.
In this area, BD presents an array of solutions for specimen and blood collection and an extensive selection of diagnostic tools, including automated culturing for blood and tuberculosis, molecular testing systems, products for microorganism identification, and drug susceptibility testing. The segment also specializes in liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media products. For cellular analysis, it offers fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, crucial for clinical oncology, immunological research, and transplantation diagnostics or monitoring.
BD's interventional segment covers a wide range of surgical and medical products, including those for hernia and soft tissue repair, biosurgery, and surgical infection prevention. It also offers biological and bioresorbable grafts, peripheral intervention products, and equipment for urology and critical care. These products are designed to improve patient outcomes and support the efficiency of medical procedures.